PCVX

Vaxcyte, Inc. is a clinical-stage vaccine innovation company based in San Carlos, California, focused on developing advanced vaccines using proprietary technologies. The company specializes in pneumococcal conjugate vaccines (PCVs), with candidates such as VAX-31 and VAX-24 aimed at preventing invasive pneumococcal disease, particularly in vulnerable populations like infants and older adults. Vaxcyte employs a cell-free protein synthesis platform to engineer complex proteins, enhancing immunological responses. In addition to its PCV franchise, Vaxcyte is developing early-stage programs targeting Group A Streptococcus and Shigella, addressing significant bacterial infections globally.